SCHEMBL1684697

SCHEMBL1684697

Cc1nc2ccccn2c1-c1csc(Nc2ccc(Cl)cc2)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.81
ALDH1A1 P00352 7/20 0.81
GAA P10253 7/20 0.81
KDM4E B2RXH2 6/20 0.81
LMNA P02545 5/20 0.81
HTT P42858 5/20 0.81
SMN1; SMN2 Q16637 5/20 0.81
HPGD P15428 3/20 0.81
MEN1 O00255 3/20 0.81
KMT2A Q03164 3/20 0.81
NPSR1 Q6W5P4 2/20 0.81
ALOX12 P18054 2/20 0.81
CDK2 P24941 3/20 0.80
PRKD3 O94806 1/20 0.80
MAP4K4 O95819 1/20 0.80
PIM1 P11309 1/20 0.80
RPS6KB1 P23443 1/20 0.80
FLT4 P35916 1/20 0.80
FLT3 P36888 1/20 0.80
MAPK8 P45983 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL18040747 0.99 MAPT (0.83) MAPTALDH1A1GAAKDM4ELMNA
SCHEMBL1684622 0.91 MAPT (0.98) MAPTALDH1A1GAAKDM4ELMNA
Bromide SCHEMBL18040791 0.90 MAPT (1.00) MAPTALDH1A1GAAKDM4ELMNA
SCHEMBL14907812 0.89 MAPT (0.81) MAPTALDH1A1GAAKDM4ELMNA
SCHEMBL1684637 0.89 PRKD3 (1.00) MAPTALDH1A1GAAKDM4ELMNA
SCHEMBL1684705 0.89 MAPT (0.81) MAPTALDH1A1GAAKDM4ELMNA
SCHEMBL1684929 0.89 MAPT (0.81) MAPTALDH1A1GAAKDM4ELMNA
SCHEMBL2355935 0.88 MAPT (0.75) MAPTALDH1A1GAAKDM4ELMNA
Bromide SCHEMBL18040669 0.88 MAPT (0.83) MAPTALDH1A1GAAKDM4ELMNA
Bromide SCHEMBL18040657 0.88 MAPT (0.83) MAPTALDH1A1GAAKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
US-20090209573-A1 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2009-08-20 US claimed
EP-1804803-A4 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2008-07-30 EP claimed
CN-101083996-A Compounds and compositions as hedgehog pathway modulators IRM LLC (BM) 2007-12-05 CN claimed
EP-1804803-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM, LLC (BM) 2007-07-11 EP claimed
WO-2006050351-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2006-05-11 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed
US-20090209573-A1 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2009-08-20 US disclosed
EP-1804803-A4 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2008-07-30 EP disclosed
CN-101083996-A Compounds and compositions as hedgehog pathway modulators IRM LLC (BM) 2007-12-05 CN disclosed
EP-1804803-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM, LLC (BM) 2007-07-11 EP disclosed
WO-2006050351-A2 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS IRM LLC (BM) 2006-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A MAPT 4026/4885ALDH1A1 2357/4885GAA 3522/4885
US-20090209573-A1 COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS GLI1, SHH, SMO MAPT 4520/4885ALDH1A1 2214/4885GAA 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.